HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma.

AbstractBACKGROUND:
Small nucleolar RNAs (snoRNAs) have been proved to play important roles in various cellular physiological process. Recently, dysregulation of snoRNA SNORA71A has been found involved in tumorigenesis of various malignant cancers. However, the emerging effects of SNORA71A in hepatocellular carcinoma (HCC) remain largely unclear. In this study, we aimed to explore the SNORA71A expression and its underlying significance in HCC.
METHODS:
Expression of SNORA71A in cell lines and clinical specimens was measured by quantitative real-time PCR. Then, all enrolled HCC patients were divided into low and high SNORA71A expression subgroups and then they were compared in the aspects of clinical features as well as survival outcome by respective statistical analysis methods.
RESULTS:
SNORA71A was significantly downexpressed in SK-HEP-1 (P = 0.001), Huh-7 (P < 0.001), Hep3B (P < 0.001), and clinical HCC specimens (P = 0.006). Comparing the clinical features between SNORA71A expression subgroups, it showed that low SNORA71A expression was significantly associated with large tumor diameter, multiple lesions, capsular invasion, bad tumor differentiation, and TNM stage (P < 0.05). Furthermore, it was found that HCC patients with lower SNORA71A expression had higher risk in postoperative tumor relapse (median time: 9.5 vs. 35.2 months; low vs. high; P < 0.001) and poor overall survival (median time: 36.8 vs. 52.9 months; low vs. high; P < 0.001). Besides, SNORA71A expression served as independent risk factors for tumor-free (HR = 0.450; 95% CI [0.263-0.770]; P = 0.004) and long-term survival (HR = 0.289; 95% CI [0.127-0.657]; P = 0.003).
CONCLUSIONS:
Our study for the first time demonstrated that downregulation of SNORA71A could serve as a novel biomarker for clinical assessment and prognostic prediction of HCC patients.
AuthorsYuan Ding, Zhongquan Sun, Sitong Zhang, Liuzhi Zhou, Qianhui Xu, Dongkai Zhou, Yanjie Li, Xin Han, Hao Xu, Yang Bai, Chang Xu, Hao Ding, Yao Ge, Weilin Wang
JournalDisease markers (Dis Markers) Vol. 2020 Pg. 8879944 ( 2020) ISSN: 1875-8630 [Electronic] United States
PMID33062075 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Yuan Ding et al.
Chemical References
  • Biomarkers, Tumor
  • RNA, Small Nucleolar
Topics
  • Biomarkers, Tumor (genetics, metabolism)
  • Carcinoma, Hepatocellular (genetics, metabolism, pathology)
  • Cell Movement
  • Cell Proliferation
  • Female
  • Follow-Up Studies
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms (genetics, metabolism, pathology)
  • Male
  • Middle Aged
  • Prognosis
  • RNA, Small Nucleolar (genetics, metabolism)
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: